Pain in Rheumatic Diseases, An Issue of Rheumatic Disease Clinics of North America (Volume 47-2)

Description:

This issue of Rheumatic Disease Clinics, guest edited by Dr. Maripat Corr, will discuss Pain in Rheumatic Diseases. This issue is one of four selected each year by series Consulting Editor, Dr. Michael Weisman. Topics discussed in this issue include, but are not limited to: Pain mechanisms in patients with rheumatic diseases, The back-pain assessment and treatment in clinical practice, Basic mechanisms of pain in osteoarthritis – experimental observations, NGF promise for management of pain in OA – clinical and experimental aspects, Pivotal role of pain in the lupus patient – cause or effect of poor outcomes, Cannabinoids-hope or hype for pain, Sex differences in Models of pain, Neuropathic pain in AS, and Relationship between inflammation and pain – RA as a model.

Table of Contents:

1.    Forthcoming Issues

2.    Foreword

3.    Preface

4.    Pain Mechanisms in Patients with Rheumatic Diseases

5.    Key points

6.    Introduction

7.    Risk factors

8.    Mechanistic studies

9.    The continuum of fibromyalgia to fibromyalgianess

10.  Clinics care points

11.  Low Back Pain in Adolescent and Geriatric Populations

12.  Key points

13.  Introduction

14.  Acute and chronic pain

15.  Adolescent spine disorders

16.  Geriatric spine disorders (spinal stenosis)

17.  Clinics care points

18.  Basic Mechanisms of Pain in Osteoarthritis: Experimental Observations and New Perspectives

19.  Key points

20.  Introduction

21.  The nervous system in osteoarthritis

22.  The role of nerve growth factor in osteoarthritis pain

23.  Neuroimmune involvement in osteoarthritis pain

24.  Clinics care points

25.  Targeting Nerve Growth Factor for Pain Management in Osteoarthritis—Clinical Efficacy and Safety

26.  Key points

27.  Background

28.  Biologic role of nerve growth factor

29.  Clinical outcomes in anti–nerve growth factor trials

30.  Early-phase trials of anti–nerve growth factor agents for hip or knee osteoarthritis

31.  Pre–Food and Drug Administration hold phase III trials of anti–nerve growth factor agents for hip or knee osteoarthritis

32.  Safety concerns and Food and Drug Administration hold

33.  Post-2015 phase III studies in knee and hip osteoarthritis

34.  Anti–nerve growth factor agents for chronic low back pain

35.  Summary

36.  Clinics care points

37.  Pain in Axial Spondyloarthritis: Insights from Immunology and Brain Imaging

38.  Key points

39.  Introduction

40.  Sources of pain in axial spondyloarthritis

41.  Pain perception

42.  Pain transmission

43.  The neuroimmune interface

44.  Central sensitization

45.  Sexual differences in chronic pain

46.  Brain imaging in chronic pain

47.  Brain imaging in ankylosing spondylitis

48.  Pharmacotherapy of pain in spondyloarthritis

49.  Summary

50.  Clinics care points

51.  The Categorization of Pain in Systemic Lupus Erythematosus

52.  Key points

53.  Musculoskeletal pain

54.  Neuropsychological sources of pain

55.  Serositis

56.  Other conditions

57.  Symptom categorization

58.  Summary

59.  Clinics care points

60.  Why It Hurts: The Mechanisms of Pain in Rheumatoid Arthritis

61.  Key points

62.  Introduction

63.  Nociception and types of pain

64.  Peripheral mechanisms of pain: inflammatory cytokines and more

65.  Central mechanisms of pain

66.  Assessing pain in rheumatoid arthritis

67.  Future areas of research

68.  Clinics care points

69.  Sexual Dimorphism in the Expression of Pain Phenotype in Preclinical Models of Rheumatoid Arthritis

70.  Key points

71.  A brief overview of rheumatoid arthritis

72.  Pain in rheumatoid arthritis

73.  Preclinical models and sexual dimorphism in the pain phenotype of rheumatoid arthritis

74.  Summary and future directions

75.  Clinics care points

76.  Cannabinoids and Pain: The Highs and Lows

77.  Key points

78.  Introduction/background

79.  Relevance

80.  Cannabinoids and their receptors

81.  Pharmacology of cannabinoids

82.  Pharmacologic or medical treatment options

83.  Complications

84.  The evidence for cannabinoids and pain

85.  New developments

86.  Summary and future directions

87.  Clinics care points

88.  Nonpharmacologic Pain Management in Inflammatory Arthritis

89.  Key points

90.  Background

91.  Self-efficacy: the foundational principle

92.  Cognitive behavioral therapy

93.  Mindfulness-based interventions

94.  Patient education

95.  Biofeedback

96.  Exercise and physical activity

97.  Massage

98.  Orthotics/splints

99.  Balneotherapy

100.               Acupuncture

101.               Sleep

102.               Depression

103.               Ineffective therapies

104.               Summary

105.               Clinics care points